20170412-lava-VISUAL-edited

NEXT-GENERATION T-CELL ENGAGERS

COMPANY PROFILE

Lava Therapeutics B.V. is a biotechnology company, founded in 2016, that creates and develops next generation γδ T cell engaging bispecific antibodies for the treatment of cancer. Our first-in-class immuno-oncology approach activates γδ T cells in a tumor target dependent manner.

The objective of Lava Therapeutics B.V is to develop potent, safe and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells.

ABOUT US

LEADERSHIP TEAM

CEO

Steve Hurly, MSc, MBA

Head of R&D

Paul Parren, PhD

CMO

Benjamin Winograd, MD, PhD

CDO

Ton Adang, PhD

CSO

Hans van der Vliet, MD, PhD

CEO

Steve Hurly, MSc, MBA

Steve Hurly brings nearly two decades of leadership experience in the life sciences industry. He served as President and Chief Executive Officer of Sesen Bio, a NASDAQ listed late stage oncology firm. Prior he served as the President and Chief Executive Officer of Viventia Bio Inc., a specialty pharmaceutical company acquired by Sesen Bio Inc in September 2016. Steve has more than 15 years of experience in the investment banking business. He has served on the board of directors of PHusis Therapeutics Inc., a private targeted small molecule therapeutics company, since May 2011. Previously, he was the Chief Executive Officer of Burrill & Co.’s Merchant Banking Division, a finance business for life science companies. He was also the head of the Life Sciences Investment Banking Practice at Boenning & Scattergood, a securities asset management and investment banking firm. He graduated from Swarthmore College with a B.A. degree in Engineering and earned an M.B.A. from the University of Chicago.

Head of R&D

Paul Parren, PhD

Paul Parren is an expert in antibody research, translational science and drug development. He is a professor of molecular immunology at the Leiden University Medical Center. Previously, he served as Genmab’s head of preclinical development and research and he was an Associate Professor at The Scripps Research Institute in La Jolla, CA. He invented and developed the approved therapeutic antibodies ofatumumab (Arzerra) and daratumumab (DARZALEX) and clinically validated antibody platform technologies for generating bispecific and enhanced-function antibodies. He contributed to preclinical development of 9 further antibodies in various stages of clinical development. He is a board member of The Antibody Society. He received his PhD from the University of Amsterdam (1992).

CMO

Benjamin Winograd, MD, PhD

Benjamin Winograd has longstanding experience in leading drug development programs in Hematology and Oncology at companies including Bristol-Myers Squibb, Pharmacia, Schering-Plough, and Celgene. Most recently he was Clinical R&D Therapeutic Area Head for Multiple Myeloma at Celgene where he led landmark studies resulting in the registration of lenalidomide (Revlimid) and pomalidamide (Pomalyst/Imnovid). Prior to that, he was instrumental in early and late development, registration and launching of cancer therapeutics including paclitaxel (TAXOL), irinotecan (Camptosar), exemestane (Aromasin), epirubicin (ELLENCE), and temozolomide (Temodar). He received his MD and PhD from the Technical University of Munich, Germany, and began his career as part of the EORTC Cooperative Group at the VU University in Amsterdam.

CDO

Ton Adang, PhD

Ton Adang worked at several biotech companies and at Merck/MSD, Schering-Plough and Organon in research and development positions with increasing responsibilities. He held leadership positions in the Lead Discovery Unit and in project management, developing a product through FDA approval and targeting new indications like breast cancer, osteoporosis as well as working with human vaccines, biosimilars and in immune oncology. He received his PhD from the University of Leiden at the Divisions of Bio-Pharmaceutical Sciences and Bio-Organic Chemistry.

CSO

Hans van der Vliet, MD, PhD

Hans van der Vliet is a professor medical oncology at the Amsterdam UMC, location VUmc. He received his MD from the University of Amsterdam in 1998 and his PhD (cum laude) and internal medicine specialization in medical oncology from the VU University in Amsterdam. He performed post-doctoral research at the Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School.

BOARD OF DIRECTORS

Laia Crespo

Reza Halse

Nanna Lüneborg

Stefan Luzi

Guido Magni

Joël Jean-Mairet

Erik van den Berg

Laia Crespo

Laia joined Sanofi Ventures in 2018 with a background in biotech investing primarily in Europe. Prior to Sanofi, Laia served as Investment Director for Ysios Capital, a Venture fund based in Barcelona, where she led investments and served on the Boards of OxThera (Sweden), Minoryx Therapeutics (Spain) and Inbiomotion (Spain), and as an Observer with AM-Pharma (The Netherlands). Earlier in her career, Laia was part of the European New Business Development team of Janssen-Cilag, a pharmaceutical company of the Johnson & Johnson group, where she assessed commercial and scientific licensing-in opportunities. Previously she worked as a researcher in the UK in companies such as Spirogen (now AstraZeneca), Medivir and UCB-Celltech.

Laia currently serves as a board observer for NodThera.

Laia graduated in Chemistry from the University of Barcelona, where she also completed a Master in Science and a PhD with honors. Laia holds an MBA from Cambridge Judge Business School, University of Cambridge.

Reza Halse

Rez has over twelve years of therapeutic discovery and development experience in the pharmaceutical and biotechnology industries through management roles in the UK and US. In the UK he established research operations and led drug discovery efforts at Xcellsyz Ltd, a venture capital backed start-up, which was sold in 2004. He then moved to Novartis Pharmaceuticals in Cambridge, MA, where he directed drug discovery projects in a variety of disease areas, ranging from diabetes to neglected infectious diseases. While at Novartis he also established innovative drug discovery collaborations with academia and non-profit organizations, in an initiative aimed at incubating new areas of research. Following Novartis, he joined a well-capitalized biotech organization, funded by a venture philanthropist, and led programs at various stages of discovery and development using an entirely virtual operating model. Rez holds a BSc in Biochemistry and a PhD in cell biology both from Newcastle University, UK. Rez currently represents the Fund on the Boards of Adheron Therapeutics, Spero Therapeutics and Project C.

Nanna Lüneborg

Nanna joined Novo Holdings in 2012, and spent four years in Novo Seeds, where she helped build a strong portfolio of seed and Series A stage companies. She led the initial investments and served on the Boards as Director or Observer at Inthera, IO Biotech, MinervaX, Pcovery, Forendo and Galecto. Nanna joined Novo Ventures in 2016 and has been involved in both private and public investments, including successful public listings of Orphazyme (ORPHA), ObsEva (OBSV), and Inventiva (IVA). She currently serves on the boards of NodThera, ReViral, Stargazer and Lava.

Prior to her time at Novo Holdings, Nanna was part of the life science investment team at Apposite Capital, a London-based venture fund, where she participated in both primary and secondary investments, with multiple deals leading to highly successful exits for the fund, including Convergence, Ulthera and Cancer Partners UK. She has previously worked at Cancer Research UK as a research analyst, and as a consultant to various biotech and healthcare venture projects during her MBA. Nanna received her PhD in Neuroscience from University College London, an MBA with distinction from University of Cambridge, and a 1st class BA from University of Oxford.

Stefan Luzi

Stefan Luzi joined Gilde Healthcare in 2015. He is focusing on venture and growth capital investments in the biopharmaceutical and life science instruments sectors. He led the investment in Lava Therapeutics B.V. and was part of several other investments. He represents Gilde on the boards of Lava Therapeutics B.V. and Lumicks B.V. Prior to joining Gilde, Stefan worked at Merck KGaA where he completed several international assignments including the Global Business Intelligence and MS Ventures divisions. Additionally, he was involved in various consulting projects spanning the pharmaceutical and chemical departments at Merck and co-moderated Merck Serono’s innovation competitions. Stefan holds a MSc in Biotechnology degree from ETH Zurich (Switzerland) and a MPhil in Bioscience Enterprise degree from the University of Cambridge (UK). He also completed a PhD program with Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge (UK), where he developed a bicyclic peptide-based drug discovery platform.

Guido Magni

Guido Magni, M.D., Ph.D., is a Partner with Versant Ventures. He brings deep experience in drug development from multiple accomplishments at leading global pharmaceutical companies including Roche and Wyeth. Guido held the position of Global Head of the Medical Science Department at Roche for 12 years and built a track record that includes the approval of 15 new drugs across various therapeutic areas during this time, including blockbuster products Cellcept, Pegasys, Mabthera, Xeloda, Herceptin, Tamiflu and Tarceva. Guido brings this critical expertise to Versant portfolio companies by providing guidance on their clinical and regulatory strategies.

Joël Jean-Mairet

Joël is managing partner and co-founder of Ysios Capital. Previously, he co-founded Glycart Biotechnology in 2001 and was its CEO until it was successfully sold to F. Hoffmann La-Roche four years later. Glycart Biotechnology was the originator of the anti-CD20 antibody – obinituzumab/Gazyva®, the first breakthrough designated drug approved by the FDA for B-CLL. He holds an MS in Biotechnology and a PhD from the Swiss Federal Institute of Technology (ETH) in Zurich.

Joël is currently on the boards of directors of Aura Biosciences, Sanifit Therapeutics, Ona Therapeutics, Executive Chairman of Inbiomotion, Chairman of SpliceBio and board observer at AM-Pharma. He has been Chairman of the board of Cellerix/Tigenix (now Takeda), board observer at Biovex (now Amgen). Joël has earned numerous awards, including the Wall Street Journal’s Europe Innovation Award in 2001.

Erik van den Berg

Erik has over twenty years of experience in the pharmaceutical industry. He is the CEO of AM-Pharma and board member of several (bio)tech companies. Previously, as a senior executive at Organon (currently Merck) he was responsible for leading the Company’s global biotechnology business development. Erik executed over 20 transactions and partnerships, most recently a $600M option to acquire AM-Pharma by Pfizer and raised more than €130M in equity and debt financing. He concluded his Masters in chemistry from the University of Utrecht and an MBA from Manchester Business School both with honors.

SCIENCE

T lymphocytes are divided in two main categories based on T cell receptor type; αß and γδ T cells. Whereas αß T cells have specific reactivity to peptides presented via HLA antigens, γδ T cells are activated by non-peptide antigens. Human γδ T cells are classified based on their receptor Vδ chain, with Vγ9Vδ2 T cells being the predominant subpopulation in circulation. These Vγ9Vδ2 T cells represent a potent class of proinflammatory immune effector cells with an immune surveillance function. Vγ9Vδ2 T cells are able to sense the presence of small phosphorylated metabolite antigens termed phosphoantigens, which are often expressed at high levels by tumor cells. Binding of the γδ T cell receptor to the butyrophilin-phosphoantigen complex leads to Vγ9Vδ2 T cell activation, tumor cell killing, secretion of pro-inflammatory cytokines and tumor-infiltration. In addition, these cells can act as antigen-presenting cells, priming the adaptive immune system.

Vγ9Vδ2 T cells can provide effective anti-tumor immune responses against both solid and haematological malignancies. The presence of Vγ9Vδ2 T cells correlates with increased survival for a wide range of cancers (Tosolini M. et al. 2017). Interestingly, Vγ9Vδ2 T cells, in contrast to αβ T cells, infiltrate tumors independent of mutational tumor load.

Support for the potential of γδ T cell-based therapies is provided by Buccheri S. et al. 2014, showing favourable clinical outcomes and low toxicity in a meta-analysis of γδ T cell-based immunotherapies both performed by adoptive cell therapies and in vivo activation with compounds such as synthetic γδ T cell ligands or aminobisphosphonates.

LAVA’s bispecific γδ T cell engagers uniformly and specifically bind to the conserved T cell receptor of Vγ9Vδ2 T cells, providing a tumor target dependent response, avoiding generalized T cell activation known to induce side effects.

Proof of principle has been established by in vitro and in/ex vivo studies in which Vγ9Vδ2 T cell engagers demonstrate potent tumor lysis of both tumor cell lines and primary patient materials.

The company is currently working on several lead bispecific Vγ9Vδ2 T cell engager candidates that are progressing towards the clinic.

PARTNERING

Lava develops proprietary bispecific Vγ9Vδ2 T-cell engagers for selected tumor targets. Pharmaceutical companies with an interest to use Lava’s Vγ9Vδ2 T-cell engagers for own tumor targets or with an interest in Lava’s lead projects should contact Lava via info@lavatherapeutics.com.

Collaborations are a key part of our business strategy and we are actively seeking new partnerships with companies that are interested in licensing our products and proprietary technologies.

NEWS

LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs

LAVA Therapeutics, Amsterdam UMC and Monash University Announce Publication of a Novel Cancer Immunotherapy Approach in Nature Cancer

Lava Therapeutics Appoints Oncology and Hematology Expert Benjamin Winograd, M.D., Ph.D., as Chief Medical Officer

Lava Therapeutics Announces Collaboration with Janssen to Develop Bi-specific Gamma-Delta T-cell Engager Therapeutics

Lava Therapeutics Appoints Immuno-Oncology Experts James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., to Advisory Board

Lava Therapeutics Raises EUR 16 Million to Advance Bispecific Gamma-Delta T Cell Engager Platform. Biologics Expert Paul Parren Joins as Head of R&D.

Lava Therapeutics licenses leading edge Vγ9Vδ2 T-cell immune oncology assets

INVESTORS

CONTACT US

+31 6 3000 3035

Yalelaan 60
3584 CM, Utrecht
[map]